Get the Stockscreener App
10.26
80.27%
-41.73
After Hours:
10.45
0.19
+1.85%
ChemoCentryx, Inc. stock is traded at $10.26, with a volume of 12,907.
It is down -80.27% in the last 24 hours and down -80.27% over the past month.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
See More
Previous Close:
$51.99
Open:
$10.2
24h Volume:
12,907
Relative Volume:
66.00
Market Cap:
$3.64B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-5.4286
EPS:
-1.89
Net Cash Flow:
-
1W Performance:
-80.27%
1M Performance:
-80.27%
6M Performance:
-80.27%
1Y Performance:
-80.27%
1-Day Range:
$10.07
$10.32
1-Week Range:
$10.07
$10.32
52-Week Range:
$10.07
$10.32
ChemoCentryx, Inc. Stock (CCXI) Company Profile
Name
ChemoCentryx, Inc.
Sector
Industry
Phone
650-210-2900
Address
850 Maude Avenue, Mountain View, CA
Compare CCXI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCXI
ChemoCentryx, Inc.
|
10.26 | 3.64B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
ChemoCentryx, Inc. Stock (CCXI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-11-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-11-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-08-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jul-07-21 | Upgrade | Stifel | Hold → Buy |
| May-07-21 | Downgrade | JP Morgan | Neutral → Underweight |
| May-07-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-07-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| May-07-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-21 | Downgrade | Stifel | Buy → Hold |
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-29-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-27-20 | Initiated | Wells Fargo | Overweight |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-19 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-19 | Reiterated | Piper Jaffray | Overweight |
| Mar-27-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-11-19 | Initiated | Piper Jaffray | Overweight |
| Sep-07-18 | Initiated | B. Riley FBR | Neutral |
| Aug-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-28-18 | Initiated | Raymond James | Strong Buy |
| May-02-18 | Initiated | H.C. Wainwright | Buy |
| Feb-21-17 | Initiated | JMP Securities | Mkt Outperform |
| May-18-15 | Upgrade | JP Morgan | Neutral → Overweight |
| May-20-13 | Reiterated | Stifel | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Buy |
View All
ChemoCentryx, Inc. Stock (CCXI) Latest News
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue - biocentury.com
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market - Citeline News & Insights
Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request - Medical Professionals Reference
US FDA Wants Tavneos Pulled From Market, Amgen Declines - Citeline News & Insights
EMA reviewing Amgen’s vasculitis drug over trial ‘data integrity’ - BioWorld MedTech
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. - Newsfile
Anca Vasculitis Drug Market Set for Dynamic Rise with Key Players ChemoCentryx, Inc. and Vifor Pharma - openPR.com
ChemoCentryx Target of Unusually High Options Trading (NASDAQ:CCXI) - 富途牛牛
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board - The Globe and Mail
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Latham-Backed Drug Developer's Statements Can't Be Proven False, N.D. Cal. Judge Finds - Law.com
Amgen's ChemoCentryx prevails in investor lawsuit centered on autoimmune drug Tavneos - Fierce Pharma
Pharma Company Beats Investor Suit Over Drug Safety Claims - Law360
ANCA Vasculitis Pipeline 2025: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight By Delveinsight Vifor Pharma, Glaxosmithkline, Amgen, Genentech, Pfizer, Chemocentryx, Biogen - Menafn
Doctored data, protest from trial observers: Lawsuit points to alleged misconduct at Amgen-bought biotech - Fierce Pharma
Buy These 3 Cheap Stocks Now - The Globe and Mail
Kodiak Copper: Supporting the Copper Demand for the AI Revolution - The Globe and Mail
Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? - The Globe and Mail
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors - Business Wire
BeiGene Enters Sublease Agreement with ChemoCentryx for Expansion - TipRanks
Bernstein Litowitz Berger & Grossmann LLP Announces Notice of Pendency of Class Action for All Persons and Entities Who Purchased or Otherwise Acquired the Common Stock of ChemoCentryx, Inc. from November 26, 2019 through May 6, 2021, inclusive - Olean Times Herald
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA - Finansavisen
Microscopic Polyangiitis (MPA) Treatment Industry to Witness - openPR.com
Amgen opts to sublease Peninsula space taken in $3.9 billion buyout - The Business Journals
ChemoCentryx (NASDAQ:CCXI) Sees Strong Trading Volume on Analyst Upgrade - 富途牛牛
RA Capital sues ChemoCentryx after biotech company's $3.9 billion sale to Amgen - The Business Journals
About Us | Laser Focus WorldImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors - FinancialContent
Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals - biocentury.com
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Foresees Noteworthy US$4.89 Billion Va - PharmiWeb.com
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading CompaniesACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics - PR Newswire
Chemocentryx presents new chemokine CXCR6 receptor antagonists - BioWorld MedTech
Member Spotlight: Q&A with Catailyst - Massachusetts Biotechnology Council
Tausif ('Tosh') Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager - PR Newswire
Northwest Healthcare REIT: Stocks Analysts Recently Downgraded on TSX (NWH-UN) - The Globe and Mail
Chemocentryx discovers new CCR6 antagonists - BioWorld MedTech
Celldex Therapeutics Appoints Rita Jain, M.D. to Board of Directors - citybiz
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch - insights.citeline.com
The top 10 biopharma M&A deals of 2022 - Fierce Pharma
Humble & Fume Announces Chief Executive Officer (CEO) Transition - The Globe and Mail
Provention Bio onboards Rita Jain, M.D., to Board of Directors - World Business Outlook
Provention Bio Appoints Rita Jain, M.D., to Board of Directors - citybiz
Special Report: Year in ReviewDespite Market Woes, Billions of Dollars in Local Deals Still Went Through - Los Angeles Business Journal
Horizon Therapeutics is up for grabs; Sanofi and Amgen are ready to use cash for bids. - Medical Marketing and Media
Horizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi - Reuters
Amgen’s Latest Acquisition Puts a Spotlight on Rare Autoimmune Disease - Amgen
Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches - Citeline News & Insights
ChemoCentryx, Inc. Stock (CCXI) Financials Data
There is no financial data for ChemoCentryx, Inc. (CCXI). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.10%
7.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):